Carcinogenesis by benzenediazonium sulfate in mice.
Benzenediazonium sulfate (BD) was given to Swiss mice by 26 subcutaneous injections of 10 micrograms/g body weight at weekly intervals. The treatment gave rise to tumors of the subcutis. The tumor incidences in the treated groups were 42% in females and 26% in males. The corresponding tumor incidences in the untreated controls were 0% in females and 2% in males. Histopathologically, the neoplasms were classified as fibrosarcomas, rhabdomyosarcomas, and osteosarcomas of the subcutaneous tissue. BD is formed during the cytochrome P-450 catalyzed metabolism of the carcinogenic 1-(phenylazo)-2-hydroxynaphthalene (Sudan I, Solvent Yellow 14), which was used as a coloring agent for food and other materials in several countries. Further, BD is a metabolic breakdown product of different classes of nitrogen-nitrogen bond- containing chemicals. BD is the fourth benzenediazonium salt found to be carcinogenic in this laboratory.
Toth
B
B
Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha 68198, USA.
Patil
K
K
Erickson
J
J
Gannett
P
P
D000818:Animals; D015197:Carcinogenicity Tests; D002273:Carcinogens / Q000737:chemistry / Q000494:pharmacology*; D003979:Diazonium Compounds / Q000737:chemistry / Q000494:pharmacology*; D005260:Female; D005354:Fibrosarcoma / Q000139:chemically induced; D008297:Male; D051379:Mice; D015394:Molecular Structure; D012516:Osteosarcoma / Q000139:chemically induced; D012208:Rhabdomyosarcoma / Q000139:chemically induced
D002273:Carcinogens; D003979:Diazonium Compounds; C035176:benzenediazonium